Thursday, May 26, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Common coronavirus infections don’t generate antibodies that effectively cross-react with SARS-CoV-2

by Medical Finance
in Coronavirus
Omicron variant found to be much less sensitive to neutralizing antibodies than Delta
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Although SARS-CoV-2 has taken the world by storm, it’s not the only coronavirus that can infect humans. But unlike SARS-CoV-2, common human coronaviruses (HCoVs) generally cause only mild disease. Now, researchers reporting in ACS Infectious Diseases have shown that infections with two different HCoVs don’t generate antibodies that effectively cross-react with SARS-CoV-2. So, prior infection with HCoVs is unlikely to protect against COVID-19 or worsen a SARS-CoV-2 infection through antibody-dependent enhancement (ADE), the researchers say.

Because SARS-CoV-2 shares significant sequence similarity with its HCoV cousins, researchers have wondered if the immune system might recognize the new coronavirus from prior bouts with HCoVs. This could re-activate memory B cells, causing them to produce antibodies that helped the person overcome previous HCoV infections, and might also help fight COVID-19. On the other hand, if the antibodies against HCoVs recognize SARS-CoV-2, but not strongly enough to generate an immune response, they could cause ADE. In this rare condition, sub-optimal antibodies actually help some viruses attach to and enter host cells, making the infection worse. Sebastien Fiedler, Tuomas Knowles and colleagues wanted to compare the strength and concentration of antibodies against HCoVs and SARS-CoV-2 in the sera of nine recovered COVID-19 patients and in three pre-pandemic sera.

The researchers used a technique called microfluidic antibody-affinity profiling, which unlike the traditionally used enzyme-linked immunosorbent assay (known as ELISA), can measure both antibody affinity and concentration independently. They found that all nine recovered COVID-19 sera samples contained moderate amounts of antibodies with high affinity to the SARS-CoV-2 spike protein. In contrast, none of the pre-pandemic sera contained high-affinity antibodies for SARS-CoV-2. All 12 sera contained low amounts of very high-affinity antibodies against two common HCoVs, indicating previous infections. Other experiments showed that these antibodies did not bind to SARS-CoV-2. The results suggest that there is no significant cross-reactivity of antibodies against common HCoVs and SARS-CoV-2, and therefore, no expected protective or adverse effects of antibody cross-reactivity for these coronaviruses, the researchers say.

Source:

American Chemical Society

Journal reference:

Denninger, V., et al. (2022) Microfluidic Antibody Affinity Profiling Reveals the Role of Memory Reactivation and Cross-Reactivity in the Defense Against SARS-CoV‑2. ACS Infectious Diseases. doi.org/10.1021/acsinfecdis.1c00486.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Perspective: COVID-19 vaccine breakthrough infections. Image Credit: Orpheus FX

New perspective on SARS-CoV-2 breakthrough infections and booster shot restoration of vaccine efficacy

by Medical Finance
May 25, 2022
0

The creation of messenger RNA (mRNA) COVID-19 vaccines was pivotal for increasing immune protection against severe acute respiratory syndrome coronavirus...

Study: The Age-Related Probability of Dying from COVID-19 among Those Infected: A Relative Survival Analysis. Image Credit: NIAID

A relative COVID-19 survival analysis

by Medical Finance
May 25, 2022
0

Coronavirus disease 2019 (COVID-19) has spread to nearly every country in the world and caused over 5.69 million deaths. The...

Study: Resilient T cell responses to B.1.1.529 (Omicron) SARS-CoV-2 variant. Image Credit: Kateryna Kon / Shutterstock

Study finds COVID booster maintains strong T cell response against Omicron

by Medical Finance
May 25, 2022
0

New study results posted to the medRxiv* preprint server found that COVID vaccine boosters increase immunity by enhancing T cell...

Study: The risk of SARS-CoV-2 Omicron variant emergence in low and middle-income countries (LMICs). Image Credit: Eve Orea/Shutterstock

Study shows several low- and middle-income countries at over 50% risk of undetected Omicron transmission

by Medical Finance
May 25, 2022
0

In a recent study posted to the medRxiv* pre-print server, a team of researchers estimated the probability of undetected emergence...

Study: Bioconjugated Nanomaterial for Targeted Diagnosis of SARS-CoV-2. Image Credit: Kateryna Kon/Shutterstock

Applications of bioconjugated nanomaterials in SARS-CoV-2 diagnostics

by Medical Finance
May 25, 2022
0

In a new study in the journal Accounts of Materials Research, researchers presented an overview of the recent advances...

Study: Waning Effectiveness of SARS-CoV-2 mRNA Vaccines in Older Adults: A Rapid Review. Image Credit: Melinda Nagy/Shutterstock

Exploring the waning effect of mRNA vaccines against COVID-19 in the elderly

by Medical Finance
May 25, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers determined the vaccine effectiveness (VE) against severe acute respiratory syndrome...

Next Post
Dog brains can detect speech and show different activity patterns to many languages

Researchers analyze the development and genetic profile of brain's immune cells

Study: Reporting Rates for VAERS Death Reports Following COVID-19 Vaccination, December 14, 2020-November 17, 2021. Image Credit: Anze Furlan / Shutterstock

CDC/FDA reports on VAERS - no association between vaccines and increased mortality

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Limit of Detection for Rapid Antigen Testing of the SARS-CoV-2 Omicron Variant. Image Credit: Nao Novoa/Shutterstock
    Determining the limit of detection for SARS-CoV-2 Omicron variant using rapid antigen tests
  • Semarion founders Tarun Vemulkar and Jeroen Verheyen
    Semarion raises £2.14 million GBP ($2.89 million USD) seed funding
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply